Safety and efficacy of combined Glaucoma Tube Shunt (Ahmed) and Fluocinolone Acetonide (Retisert™) implantation compared to Ahmed Alone in patients with uveitic glaucoma : A retrospective study

Trial Profile

Safety and efficacy of combined Glaucoma Tube Shunt (Ahmed) and Fluocinolone Acetonide (Retisert™) implantation compared to Ahmed Alone in patients with uveitic glaucoma : A retrospective study

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Dec 2016

At a glance

  • Drugs Fluocinolone acetonide (Primary)
  • Indications Open-angle glaucoma; Uveitis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Dec 2016 New trial record
    • 01 Dec 2016 Primary endpoint Number of (IOP-lowering medications at 6 months) has not been met according to the results published in the Ophthalmology and Therapy.
    • 01 Dec 2016 Primary endpoint Visual acuity (VA) at 6 months has not been met according to the results published in the Ophthalmology and Therapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top